To investigate the long-term follow-up results of Suhuang Zhike capsule in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD).Methods:From September 2014 to September 2015,a total of 90 patients with acute exacerbation of COPD in our hospital were randomly divided into treatment group and control group,with 45 cases in each group.The patients in the control group were treated with routine therapy.The patients in the treatment group were treated with Suhuang Zhike capsule in addition to routine therapy,1.35 g / time,3 times a day for 8 weeks.At the end of the course,more than 12 months of follow-up observation was performed.Results:During the follow-up period,the frequency of recurrence and relapse rate of the treatment group were significantly lower than those of the control group (P<0.01).The FVC,FEV1,FEV1 / FVC,MVV of the treatment group were significantly higher and RV and RV / TLC were significantly lower,compared with the control group (P<0.05).In addition,the levels of serum immunoglobulin IgG,IgA,IgM and CD3+,CD4+,CD4+/CD8+ in the treatment group were significantly higher than those of pre-treatment and the control group (P<0.05).Furthermore,the score of the quality of life assessment of the treatment group was significantly reduced,6-min walking distance was significantly increased,compared with those of pre-treatment and the control group,the differences were statistically significant (P<0.05).Conclusion:Suhuang Zhike capsule can improve pulmonary function,immune function and quality of life of patients with COPD and reduce the number of recurrent cases and recurrence rate.